IN THE CLAIMS

Please amend the claims as follows:

Claim 1 (Currently Amended): ~~Use of an~~ A method of treating or preventing at least one disease selected from the group consisting of diabetes type II, obesity, and appetite regulation, in a subject in need thereof, comprising administering at least one aryl dicarboxamide of formula (I):



(I)

as well as its geometrical isomers, its optically active forms as enantiomers, diastereomers and its racemate forms, as well as pharmaceutically acceptable salts ~~and pharmaceutically active derivatives~~ thereof, wherein

A is an aminocarbonyl moiety of the formula –CO-NHR$^6$, wherein R$^6$ is $C_6$-$C_{15}$ alkyl, $C_2$-$C_{15}$-alkenyl, $C_2$-$C_{15}$-alkynyl, a 3-8 membered cycloalkyl, $C_1$-$C_6$ alkyl-(3-8 membered) cycloalkyl, phenyl, $C_1$-$C_{12}$ alkyl phenyl, $C_2$-$C_6$-alkenyl phenyl, or $C_2$-$C_6$-alkynyl phenyl;

Cy is an aryl, heteroaryl, aryl-heteroaryl, heteroaryl-aryl, aryl-aryl, cycloalkyl or heterocycle group;

n is either 0 or 1;

R$^1$ and R$^2$ are independently from each other [[is]] selected from the group consisting of hydrogen [[or]] and $C_1$-$C_6$-alkyl;

R$^3$ is selected from the group consisting of $C_1$-$C_6$-alkyl, $C_2$-$C_6$-alkenyl, $C_2$-$C_6$-alkynyl, $C_1$-$C_6$-alkoxy, $C_1$-$C_6$-alkyl amine, $C_1$-$C_6$-alkyl alkoxy, aryl, heteroaryl, saturated ~~or unsaturated~~ 3-8-membered cycloalkyl, unsaturated 3-8-membered cycloalkyl, 3-8-membered

heterocycloalkyl, $C_1$-$C_6$-alkyl aryl, $C_1$-$C_6$-alkyl heteroaryl, $C_2$-$C_6$-alkenyl aryl, $C_2$-$C_6$-alkenyl heteroaryl, $C_2$-$C_6$-alkynyl aryl, $C_2$-$C_6$-alkynyl heteroaryl, $C_1$-$C_6$-alkyl cycloalkyl, $C_1$-$C_6$-alkyl heterocycloalkyl, $C_2$-$C_6$-alkenyl cycloalkyl, $C_2$-$C_6$-alkenyl heterocycloalkyl, $C_2$-$C_6$-alkynyl cycloalkyl, and $C_2$-$C_6$-alkynyl heterocycloalkyl;

$R^4$ and $R^5$ are each independently from each other selected from the group consisting of H, hydroxy, $C_1$-$C_6$ alkyl, carboxy, $C_1$-$C_6$ alkoxy, $C_1$-$C_3$ alkyl carboxy, $C_2$-$C_3$ alkenyl carboxy, $C_2$-$C_3$ alkynyl carboxy, and amino, or $R^4$ and $R^5$ may form an unsaturated or saturated heterocyclic ring, whereby at least one of $R^4$ or $R^5$ is not a hydrogen or $C_1$-$C_6$ alkyl;

~~for the preparation of a medicament for the treatment and/or prevention of metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes, inadequate glucose tolerance, hyperlipidemia, hypertriglyceridemia, hypercholestero-lemia, obesity, polycystic ovary syndrome (PCOS)~~ to the subject in an amount sufficient to treat or prevent the at least one disease.

Claim 2 (Currently Amended): The method of claim 1, wherein the method is a method of treating ~~Use of an aryl dicarboxamide according to claim 1 a for the preparation of a medicament for the treatment and/or prevention of diabetes type II, obesity or for appetite regulation~~.

Claim 3 (Currently Amended): A method of treating or preventing at least one disease selected from the group consisting of diabetes, inadequate glucose tolerance, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, and polycystic ovary syndrome, in a subject in need thereof, comprising, administering at least one aryl dicarboxamide of formula (I):



(I)

as well as its geometrical isomers, its optically active forms as enantiomers, diastereomers and its racemate forms, as well as pharmaceutically acceptable salts thereof, wherein

A is an aminocarbonyl moiety of the formula $-CO-NHR^6$, wherein $R^6$ is $C_6$-$C_{15}$ alkyl, $C_2$-$C_{15}$-alkenyl, $C_2$-$C_{15}$-alkynyl, a 3-8 membered cycloalkyl, $C_1$-$C_6$ alkyl-(3-8 membered) cycloalkyl, phenyl, $C_1$-$C_{12}$ alkyl phenyl, $C_2$-$C_6$-alkenyl phenyl, or $C_2$-$C_6$-alkynyl phenyl;

Cy is an aryl, heteroaryl, aryl-heteroaryl, heteroaryl-aryl, aryl-aryl, cycloalkyl or heterocycle group;

n is either 0 or 1;

$R^1$ and $R^2$ are independently from each other selected from the group consisting of hydrogen and $C_1$-$C_6$-alkyl;

$R^3$ is selected from the group consisting of $C_1$-$C_6$-alkyl, $C_2$-$C_6$-alkenyl, $C_2$-$C_6$-alkynyl, $C_1$-$C_6$-alkoxy, $C_1$-$C_6$-alkyl amine, $C_1$-$C_6$-alkyl alkoxy, aryl, heteroaryl, saturated 3-8-membered cycloalkyl, unsaturated 3-8-membered cycloalkyl, 3-8-membered heterocycloalkyl, $C_1$-$C_6$-alkyl aryl, $C_1$-$C_6$-alkyl heteroaryl, $C_2$-$C_6$-alkenyl aryl, $C_2$-$C_6$-alkenyl heteroaryl, $C_2$-$C_6$-alkynyl aryl, $C_2$-$C_6$-alkynyl heteroaryl, $C_1$-$C_6$-alkyl cycloalkyl, $C_1$-$C_6$-alkyl heterocycloalkyl, $C_2$-$C_6$-alkenyl cycloalkyl, $C_2$-$C_6$-alkenyl heterocycloalkyl, $C_2$-$C_6$-alkynyl cycloalkyl, and $C_2$-$C_6$-alkynyl heterocycloalkyl;

$R^4$ and $R^5$ are each independently from each other selected from the group consisting of H, hydroxy, $C_1$-$C_6$ alkyl, carboxy, $C_1$-$C_6$ alkoxy, $C_1$-$C_3$ alkyl carboxy, $C_2$-$C_3$ alkenyl

carboxy, $C_2$-$C_3$ alkynyl carboxy, and amino, or $R^4$ and $R^5$ may form an unsaturated or saturated heterocyclic ring, whereby at least one of $R^4$ or $R^5$ is not a hydrogen or $C_1$-$C_6$ alkyl, to the subject in an amount sufficient to treat or prevent the at least one disease ~~Use of an aryl dicarboxamide according to claim 1 for the preparation of a pharmaceutical composition for the modulation of the activity of PTPs~~.

Claim 4 (Currently Amended): ~~Use according to~~ The method of claim 3, wherein the method is a method of treating ~~wherein the PTP is PTP1B~~.

Claim 5 (Canceled).

Claim 6 (Currently Amended): A method of treating or preventing at least one metabolic disorder mediated by insulin resistance or hyperglycemia, in a subject in need thereof, comprising, administering at least one aryl dicarboxamide of formula (I):



(I)

as well as its geometrical isomers, its optically active forms as enantiomers, diastereomers and its racemate forms, as well as pharmaceutically acceptable salts thereof, wherein

A is an aminocarbonyl moiety of the formula –CO-NHR$^6$, wherein $R^6$ is $C_6$-$C_{15}$ alkyl, $C_2$-$C_{15}$-alkenyl, $C_2$-$C_{15}$-alkynyl, a 3-8 membered cycloalkyl, $C_1$-$C_6$ alkyl-(3-8 membered) cycloalkyl, phenyl, $C_1$-$C_{12}$ alkyl phenyl, $C_2$-$C_6$-alkenyl phenyl, or $C_2$-$C_6$-alkynyl phenyl;

Cy is an aryl, heteroaryl, aryl-heteroaryl, heteroaryl-aryl, aryl-aryl, cycloalkyl or heterocycle group;

n is either 0 or 1;

$R^1$ and $R^2$ are independently from each other selected from the group consisting of hydrogen and $C_1$-$C_6$-alkyl;

$R^3$ is selected from the group consisting of $C_1$-$C_6$-alkyl, $C_2$-$C_6$-alkenyl, $C_2$-$C_6$-alkynyl, $C_1$-$C_6$-alkoxy, $C_1$-$C_6$-alkyl amine, $C_1$-$C_6$-alkyl alkoxy, aryl, heteroaryl, saturated 3-8-membered cycloalkyl, unsaturated 3-8-membered cycloalkyl, 3-8-membered heterocycloalkyl, $C_1$-$C_6$-alkyl aryl, $C_1$-$C_6$-alkyl heteroaryl, $C_2$-$C_6$-alkenyl aryl, $C_2$-$C_6$-alkenyl heteroaryl, $C_2$-$C_6$-alkynyl aryl, $C_2$-$C_6$-alkynyl heteroaryl, $C_1$-$C_6$-alkyl cycloalkyl, $C_1$-$C_6$-alkyl heterocycloalkyl, $C_2$-$C_6$-alkenyl cycloalkyl, $C_2$-$C_6$-alkenyl heterocycloalkyl, $C_2$-$C_6$-alkynyl cycloalkyl, and $C_2$-$C_6$-alkynyl heterocycloalkyl;

$R^4$ and $R^5$ are each independently from each other selected from the group consisting of H, hydroxy, $C_1$-$C_6$ alkyl, carboxy, $C_1$-$C_6$ alkoxy, $C_1$-$C_3$ alkyl carboxy, $C_2$-$C_3$ alkenyl carboxy, $C_2$-$C_3$ alkynyl carboxy, and amino, or $R^4$ and $R^5$ may form an unsaturated or saturated heterocyclic ring, whereby at least one of $R^4$ or $R^5$ is not a hydrogen or $C_1$-$C_6$ alkyl,

to the subject in an amount sufficient to treat or prevent the at least one disorder

~~Use according to claim 4 for the treatment or prevention of disorders mediated by PTP1B~~.

Claim 7 (Currently Amended): ~~Use according to any of claims 1 to 6~~ The method of claim 1, wherein $R^1$ and $R^2$ are each H.

Claim 8 (Currently Amended): ~~Use according to any of claims 1 to 7~~ The method of claim 1, wherein Cy is selected from the group consisting of phenyl, thiazolyl, phenyl-thiazolyl, and thiazolyl-phenyl.

Claim 9 (Currently Amended): ~~Use according to any of claims 1 to 8~~ The method of claim 1, wherein A is a moiety of the formula –CO-NHR$^6$, wherein R$^6$ is $C_6$-$C_{15}$ alkyl, $C_2$-$C_{15}$-alkenyl, $C_2$-$C_{15}$-alkynyl, a 3-8 membered cycloalkyl, $C_1$-$C_6$ alkyl-(3-8 membered) cycloalkyl, phenyl, $C_1$-$C_{12}$ alkyl phenyl, $C_2$-$C_6$-alkenyl phenyl, or $C_2$-$C_6$-alkynyl phenyl.

Claim 10 (Currently Amended): An aryl dicarboxamide according to any of the formulae (Ia), (Ib) or (Ic):




(Ia) (Ib) (Ic)

wherein

A is an aminocarbonyl moiety of the formula –CO-NHR$^6$ wherein R$^6$ is $C_6$-$C_{15}$ alkyl, $C_2$-$C_{15}$-alkenyl, $C_2$-$C_{15}$-alkynyl, a 3-8 membered cycloalkyl, $C_1$-$C_6$ alkyl-(3-8 membered) cycloalkyl, phenyl, $C_1$-$C_{12}$ alkyl phenyl, $C_2$-$C_6$-alkenyl phenyl, or $C_2$-$C_6$-alkynyl phenyl;

Cy is an aryl, heteroaryl, aryl-heteroaryl, heteroaryl-aryl, aryl-aryl, cycloalkyl or heterocycle group;

n is either 0 or 1;

$R^1$ and $R^2$ are independently from each other [[is]] selected from the group consisting of hydrogen [[or]] and $C_1$-$C_6$-alkyl;

$R^3$ is selected from the group consisting of $C_1$-$C_6$-alkyl, $C_2$-$C_6$-alkenyl, $C_2$-$C_6$-alkynyl, $C_1$-$C_6$-alkoxy, $C_1$-$C_6$-alkyl amine, $C_1$-$C_6$-alkyl alkoxy, aryl, heteroaryl, saturated ~~or unsaturated~~ 3-8-membered cycloalkyl, unsaturated 3-8 membered cycloalkyl, 3-8-membered heterocycloalkyl, an acyl moiety, $C_1$-$C_6$-alkyl aryl, $C_1$-$C_6$-alkyl heteroaryl, $C_2$-$C_6$-alkenyl aryl, $C_2$-$C_6$-alkenyl heteroaryl, $C_2$-$C_6$-alkynyl aryl, $C_2$-$C_6$-alkynyl heteroaryl, $C_1$-$C_6$-alkyl cycloalkyl, $C_1$-$C_6$-alkyl heterocycloalkyl, $C_2$-$C_6$-alkenyl cycloalkyl, $C_2$-$C_6$-alkenyl heterocycloalkyl, $C_2$-$C_6$-alkynyl cycloalkyl, and $C_2$-$C_6$-alkynyl heterocycloalkyl.

Claim 11 (Currently Amended): An aryl dicarboxamide according to formula (Ib) or (Ic):




(Ib) (Ic)

wherein

A is an aminocarbonyl moiety of the formula –CO-NHR$^6$ wherein R$^6$ is $C_6$-$C_{15}$ alkyl, $C_2$-$C_{15}$-alkenyl, $C_2$-$C_{15}$-alkynyl, a 3-8 membered cycloalkyl, $C_1$-$C_6$ alkyl-(3-8 membered) cycloalkyl, phenyl, $C_1$-$C_{12}$ alkyl phenyl, $C_2$-$C_6$-alkenyl phenyl, or a $C_2$-$C_6$-alkynyl phenyl;

Cy is an aryl, heteroaryl, aryl-heteroaryl, heteroaryl-aryl, aryl-aryl, cycloalkyl or heterocycle group;

n is either 0 or 1;

$R^1$ and $R^2$ are independently from each other is selected from the group consisting of hydrogen [[or]] and $C_1$-$C_6$-alkyl;

$R^3$ is selected from the group consisting of $C_1$-$C_6$-alkyl, $C_2$-$C_6$-alkenyl, $C_2$-$C_6$-alkynyl, $C_1$-$C_6$-alkoxy, $C_1$-$C_6$-alkyl amine, $C_1$-$C_6$-alkyl alkoxy, aryl, heteroaryl, saturated ~~or unsaturated~~ 3-8-membered cycloalkyl, unsaturated 3-8-membered cycloalkyl, 3-8-membered heterocycloalkyl, an acyl moiety, $C_1$-$C_6$-alkyl aryl, $C_1$-$C_6$-alkyl heteroaryl, $C_2$-$C_6$-alkenyl aryl, $C_2$-$C_6$-alkenyl heteroaryl, $C_2$-$C_6$-alkynyl aryl, $C_2$-$C_6$-alkynyl heteroaryl, $C_1$-$C_6$-alkyl cycloalkyl, $C_1$-$C_6$-alkyl heterocycloalkyl, $C_2$-$C_6$-alkenyl cycloalkyl, $C_2$-$C_6$-alkenyl heterocycloalkyl, $C_2$-$C_6$-alkynyl cycloalkyl, and $C_2$-$C_6$-alkynyl heterocycloalkyl.

Claim 12 (Currently Amended): [[An]] The aryl dicarboxamide according to claim 10 ~~or 11~~, wherein $R^1$ and $R^2$ are each H.

Claim 13 (Currently Amended): [[An]] The aryl dicarboxamide according to ~~any of claims 10 to 12~~ claim 10, wherein Cy is selected from the group consisting of phenyl, thiazolyl, phenyl-thiazolyl, and thiazolyl-phenyl.

Claim 14 (Currently Amended): [[An]] The aryl dicarboxamide according to claim 13, wherein $R^6$ is selected from the group consisting of $C_8$-$C_{12}$ alkyl, $C_1$-$C_4$ alkyl phenyl which may be substituted by $C_1$-$C_8$ alkyl, [[or]] and phenoxy.

Claim 15 (Currently Amended): An aryl dicarboxamide ~~according to any of the preceding claims~~ selected from the group consisting of :

5-[(3-cyclopentylpropanoyl)(4-{[(4-phenoxybenzyl)amino]carbonyl}benzyl)amino]-2-hydroxybenzoic acid

5-[(3-cyclopentylpropanoyl)(4-{[(4-phenoxybenzyl)amino]carbonyl}benzyl)amino]-2-hydroxybenzoic acid

[4-({{[2-(4-{[(4-pentylbenzyl)amino]carbonyl}phenyl)-1,3-thiazol-4-yl]methyl}-[(2*E*)-3-phenylprop-2-enoyl]amino}methyl)phenoxy]acetic acid

5-[(3-cyclopentylpropanoyl)(4-{[(4-pentylbenzyl)amino]carbonyl}benzyl)amino]-2-hydroxybenzoic acid

2-hydroxy-5-{(4-{[(4-pentylbenzyl)amino]carbonyl}benzyl)[4-(trifluoromethyl)-benzoyl]amino}benzoic acid

2-hydroxy-5-[[(4-{[(4-phenoxybenzyl)amino]carbonyl}-1,3-thiazol-2-yl)methyl](3-phenylpropanoyl)amino]benzoic acid

5-{benzoyl[(4-{[(4-phenoxybenzyl)amino]carbonyl}-1,3-thiazol-2-yl)methyl]-amino}-2-hydroxybenzoic acid

2-hydroxy-5-{[(4-{[(4-phenoxybenzyl)amino]carbonyl}-1,3-thiazol-2-yl)methyl][4-(trifluoromethyl)benzoyl]amino}benzoic acid

5-[(cyclohexylcarbonyl)(4-{[(4-phenoxybenzyl)amino]carbonyl}benzyl)amino]-2-hydroxybenzoic acid

2-hydroxy-5-[(4-{[(4-phenoxybenzyl)amino]carbonyl}benzyl)(3-phenylpropanoyl)-amino]benzoic acid

5-[benzoyl(4-{[(4-phenoxybenzyl)amino]carbonyl}benzyl)amino]-2-hydroxybenzoic acid

5-[acetyl(4-{[(4-phenoxybenzyl)amino]carbonyl}benzyl)amino]-2-hydroxybenzoic acid

5-[(4-cyanobenzoyl)(4-{[(4-phenoxybenzyl)amino]carbonyl}benzyl)amino]-2-hydroxybenzoic acid

2-hydroxy-5-[(phenoxyacetyl)(4-{[(4-phenoxybenzyl)amino]carbonyl}benzyl)-amino]-benzoic acid

2-hydroxy-5-{(4-{[(4-phenoxybenzyl)amino]carbonyl}benzyl)[4-(trifluoromethyl)-benzoyl]amino}benzoic acid

2-hydroxy-5-{(4-{[(4-phenoxybenzyl)amino]carbonyl}benzyl)[(2*E*)-3-phenylprop-2-enoyl]amino}benzoic acid

5-[(N,N-dimethylglycyl)(4-{[(4-phenoxybenzyl)amino]carbonyl}benzyl)amino]-2-hydroxybenzoic acid

2-hydroxy-5-[(3-methylbut-2-enoyl)(4-{[(4-phenoxybenzyl)amino]carbonyl}benzyl)-amino]benzoic acid

2-hydroxy-5-{[{4-[(octylamino)carbonyl]benzyl}(phenoxyacetyl)amino]methyl}-benzoic acid

2-hydroxy-5-({{4-[(octylamino)carbonyl]benzyl}[4-(trifluoromethyl)benzoyl]-amino}methyl)benzoic acid

2-hydroxy-5-({{4-[(octylamino)carbonyl]benzyl}[(2*E*)-3-phenylprop-2-enoyl]-amino}methyl)benzoic acid

5-{[(3-cyclopentylpropanoyl)(4-{[(4-pentylbenzyl)amino]carbonyl}benzyl)-amino]methyl}-2-hydroxybenzoic acid

2-hydroxy-5-{[(4-{[(4-pentylbenzyl)amino]carbonyl}benzyl)(phenoxyacetyl)-amino]methyl}benzoic acid

2-hydroxy-5-({(4-{[(4-pentylbenzyl)amino]carbonyl}benzyl)[4-(trifluoromethyl)-benzoyl]amino}methyl)benzoic acid

2-hydroxy-5-{[(3-methylbut-2-enoyl)(4-{[(4-pentylbenzyl)amino]carbonyl}-benzyl)amino]methyl}benzoic acid

5-{[(3-cyclopentylpropanoyl)(4-{[(4-phenylbutyl)amino]carbonyl}benzyl)-amino]methyl}-2-hydroxybenzoic acid

2-hydroxy-5-({[(4-{[(4-pentylbenzyl)amino]carbonyl}-1,3-thiazol-2-yl)methyl][(2*E*)-3-phenylprop-2-enoyl]amino}methyl)benzoic acid

[4-({(4-{[(4-phenoxybenzyl)amino]carbonyl}benzyl)[4-(trifluoromethyl)benzoyl]-amino}methyl)phenoxy]acetic acid

2-hydroxy-5-[(4-{[(4-pentylbenzyl)amino]carbonyl}benzyl)(3-phenylpropanoyl)-amino]benzoic acid

4-[(3-cyclopentylpropanoyl)(4-{[(4-pentylbenzyl)amino]carbonyl}benzyl)amino]-2-hydroxybenzoic acid

2-hydroxy-4-{(4-{[(4-pentylbenzyl)amino]carbonyl}benzyl)[4-(trifluoromethyl)-benzoyl]amino}benzoic acid

2-hydroxy-5-[{[2-(4-{[(4-pentylbenzyl)amino]carbonyl}phenyl)-1,3-thiazol-4-yl]methyl}(phenoxyacetyl)amino]benzoic acid

2-hydroxy-5-{{[2-(4-{[(4-pentylbenzyl)amino]carbonyl}phenyl)-1,3-thiazol-4-yl]methyl}[4-(trifluoromethyl)benzoyl]amino}benzoic acid

5-([(6-chloropyridin-3-yl)carbonyl]{[2-(4-{[(4-pentylbenzyl)amino]carbonyl}-phenyl)-1,3-thiazol-4-yl]methyl}amino)-2-hydroxybenzoic acid

5-((4-cyanobenzoyl){[2-(4-{[(4-pentylbenzyl)amino]carbonyl}phenyl)-1,3-thiazol-4-yl]methyl}amino)-2-hydroxybenzoic acid

2-hydroxy-5-((3-methylbut-2-enoyl){[2-(4-{[(4-pentylbenzyl)amino]carbonyl}-phenyl)-1,3-thiazol-4-yl]methyl}amino)benzoic acid

5-((3-cyclopentylpropanoyl){[2-(4-{[(4-phenoxybenzyl)amino]carbonyl}phenyl)-1,3-thiazol-4-yl]methyl}amino)-2-hydroxybenzoic acid

2-hydroxy-5-{{[2-(4-{[(4-phenoxybenzyl)amino]carbonyl}phenyl)-1,3-thiazol-4-yl]methyl}[4-(trifluoromethyl)benzoyl]amino}benzoic acid

2-hydroxy-5-[{[2-(4-{[(4-phenoxybenzyl)amino]carbonyl}phenyl)-1,3-thiazol-4-yl]methyl}(3-phenylpropanoyl)amino]benzoic acid

5-(benzoyl{[2-(4-{[(4-phenoxybenzyl)amino]carbonyl}phenyl)-1,3-thiazol-4-yl]methyl}amino)-2-hydroxybenzoic acid

[4-({{[2-(4-{[(4-pentylbenzyl)amino]carbonyl}phenyl)-1,3-thiazol-4-yl]methyl}[4-(trifluoromethyl)benzoyl]amino}methyl)phenoxy]acetic acid

(4-{[{[2-(4-{[(4-pentylbenzyl)amino]carbonyl}phenyl)-1,3-thiazol-4-yl]methyl}(3-phenylpropanoyl)amino]methyl}phenoxy)acetic acid

[4-({{[2-(4-{[(4-phenylbutyl)amino]carbonyl}phenyl)-1,3-thiazol-4-yl]methyl}[4-(trifluoromethyl)benzoyl]amino}methyl)phenoxy]acetic acid

(4-{[{[2-(4-{[(4-phenylbutyl)amino]carbonyl}phenyl)-1,3-thiazol-4-yl]methyl}(3-phenylpropanoyl)amino]methyl}phenoxy)acetic acid

[4-({{[2-(4-{[(4-phenylbutyl)amino]carbonyl}phenyl)-1,3-thiazol-4-yl]methyl}[(2*E*)-3-phenylprop-2-enoyl]amino}methyl)phenoxy]acetic acid

{4-[((N,N-dimethylglycyl){[2-(4-{[(4-phenylbutyl)amino]carbonyl}phenyl)-1,3-thiazol-4-yl]methyl}amino)methyl]phenoxy}acetic acid

{4-[((cyclohexylcarbonyl){[2-(4-{[(4-phenylbutyl)amino]carbonyl}phenyl)-1,3-thiazol-4-yl]methyl}amino)methyl]phenoxy}acetic acid

{4-[((phenoxyacetyl){[2-(4-{[(4-phenoxybenzyl)amino]carbonyl}phenyl)-1,3-thiazol-4-yl]methyl}amino)methyl]phenoxy}acetic acid

[4-({{[2-(4-{[(4-phenoxybenzyl)amino]carbonyl}phenyl)-1,3-thiazol-4-yl]methyl}[4-(trifluoromethyl)benzoyl]amino}methyl)phenoxy]acetic acid

(4-{[{[2-(4-{[(4-phenoxybenzyl)amino]carbonyl}phenyl)-1,3-thiazol-4-yl]methyl}(3-phenylpropanoyl)amino]methyl}phenoxy)acetic acid

{4-[((cyclohexylcarbonyl){[2-(4-{[(4-phenoxybenzyl)amino]carbonyl}phenyl)-1,3-thiazol-4-yl]methyl}amino)methyl]phenoxy}acetic acid

[4-({[(2-{4-[(octylamino)carbonyl]phenyl}-1,3-thiazol-4-yl)methyl][4-(trifluoromethyl)benzoyl]amino}methyl)phenoxy]acetic acid; and

(4-{[[(2-{4-[(octylamino)carbonyl]phenyl}-1,3-thiazol-4-yl)methyl](3-phenylpropanoyl)amino]methyl}phenoxy)acetic acid.

Claim 16 (Currently Amended): [[An]] A pharmaceutical composition comprising at least one aryl dicarboxamide according to claim 11 and a pharmaceutically acceptable carrier, diluent, excipient, or combination thereof ~~aryl dicarboxamide according to any of the claims 10 to 15 for use as a medicament~~.

Claim 17 (Currently Amended): A pharmaceutical composition ~~containing~~ comprising at least one aryl dicarboxamide according to ~~any of claims 10 to 15~~ claim 10 and a pharmaceutically acceptable carrier, diluent, [[or]] excipient, or combination thereof.

Claim 18 (Currently Amended): A method of preparing [[an]] the aryl dicarboxamide of formula (I) ~~according to any of claims 10 to 15~~, comprising ~~the~~

~~de-protection and/or tansformation step of~~ deprotecting, transforming, or deprotecting and transforming (I') to form the aryl dicarboxamide (Ia):




(I') (I)

wherein ~~$R^1$, $R^2$, $R^3$, $R^4$, $R^5$, $R^{4'}$, $R^{5'}$, n and Cy are as above defined and~~ FG is A or a leaving group,

wherein

A is an aminocarbonyl moiety of the formula –CO-NHR$^6$, wherein R$^6$ is $C_6$-$C_{15}$ alkyl, $C_2$-$C_{15}$-alkenyl, $C_2$-$C_{15}$-alkynyl, a 3-8 membered cycloalkyl, $C_1$-$C_6$ alkyl-(3-8 membered) cycloalkyl, phenyl, $C_1$-$C_{12}$ alkyl phenyl, $C_2$-$C_6$-alkenyl phenyl, or $C_2$-$C_6$-alkynyl phenyl;

Cy is an aryl, heteroaryl, aryl-heteroaryl, heteroaryl-aryl, aryl-aryl, cycloalkyl or heterocycle group;

n is either 0 or 1;

R$^1$ and R$^2$ are independently from each other is selected from the group consisting of hydrogen and $C_1$-$C_6$-alkyl;

R$^3$ is selected from the group consisting of $C_1$-$C_6$-alkyl, $C_2$-$C_6$-alkenyl, $C_2$-$C_6$-alkynyl, $C_1$-$C_6$-alkoxy, $C_1$-$C_6$-alkyl amine, $C_1$-$C_6$-alkyl alkoxy, aryl, heteroaryl, saturated 3-8-membered cycloalkyl, unsaturated 3-8-membered cycloalkyl, 3-8-membered

heterocycloalkyl, $C_1$-$C_6$-alkyl aryl, $C_1$-$C_6$-alkyl heteroaryl, $C_2$-$C_6$-alkenyl aryl, $C_2$-$C_6$-alkenyl heteroaryl, $C_2$-$C_6$-alkynyl aryl, $C_2$-$C_6$-alkynyl heteroaryl, $C_1$-$C_6$-alkyl cycloalkyl, $C_1$-$C_6$-alkyl heterocycloalkyl, $C_2$-$C_6$-alkenyl cycloalkyl, $C_2$-$C_6$-alkenyl heterocycloalkyl, $C_2$-$C_6$-alkynyl cycloalkyl, and $C_2$-$C_6$-alkynyl heterocycloalkyl; and wherein

$R^4$ and $R^5$ are each independently from each other selected from the group consisting of H, hydroxy, $C_1$-$C_6$ alkyl, carboxy, $C_1$-$C_6$ alkoxy, $C_1$-$C_3$ alkyl carboxy, $C_2$-$C_3$ alkenyl carboxy, $C_2$-$C_3$ alkynyl carboxy, and amino, or $R^4$ and $R^5$ may form an unsaturated or saturated heterocyclic ring, whereby at least one of $R^4$ or $R^5$ is not a hydrogen or $C_1$-$C_6$ alkyl.

Claim 19 (New): The aryl dicarboxamide according to claim 11, wherein $R^1$ and $R^2$ are each H.

Claim 20 (New): The aryl dicarboxamide according to claim 11, wherein Cy is selected from the group consisting of phenyl, thiazolyl, phenyl-thiazolyl, and thiazolyl-phenyl.

Claim 21 (New): The aryl dicarboxamide according to claim 20, wherein $R^6$ is selected from the group consisting of $C_8$-$C_{12}$ alkyl, $C_1$-$C_4$ alkyl phenyl which may be substituted by $C_1$-$C_8$ alkyl, and phenoxy.

Claim 22 (New): The method of claim 3, wherein $R^1$ and $R^2$ are each H.

Claim 23 (New): The method of claim 6, wherein $R^1$ and $R^2$ are each H.

Claim 24 (New): The method of claim 3, wherein Cy is selected from the group consisting of phenyl, thiazolyl, phenyl-thiazolyl, and thiazolyl-phenyl.

Claim 25 (New): The method of claim 6, wherein Cy is selected from the group consisting of phenyl, thiazolyl, phenyl-thiazolyl, and thiazolyl-phenyl.

Claim 26 (New): The method of claim 3, wherein A is a moiety of the formula –CO-$NHR^6$, wherein $R^6$ is $C_6$-$C_{15}$ alkyl, $C_2$-$C_{15}$-alkenyl, $C_2$-$C_{15}$-alkynyl, a 3-8 membered cycloalkyl, $C_1$-$C_6$ alkyl-(3-8 membered) cycloalkyl, phenyl, $C_1$-$C_{12}$ alkyl phenyl, $C_2$-$C_6$-alkenyl phenyl, or $C_2$-$C_6$-alkynyl phenyl.

Claim 27 (New): The method of claim 6, wherein A is a moiety of the formula –CO-$NHR^6$, wherein $R^6$ is $C_6$-$C_{15}$ alkyl, $C_2$-$C_{15}$-alkenyl, $C_2$-$C_{15}$-alkynyl, a 3-8 membered cycloalkyl, $C_1$-$C_6$ alkyl-(3-8 membered) cycloalkyl, phenyl, $C_1$-$C_{12}$ alkyl phenyl, $C_2$-$C_6$-alkenyl phenyl, or $C_2$-$C_6$-alkynyl phenyl.

Claim 28 (New): The method of claim 6, wherein the method is a method of treating.